Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 6/20 | 0.57 |
| ▸ | GFER | P55789 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 12/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27787411 | 0.80 | MEN1 (0.60) | MEN1KMT2AKDM4EGAAGFER | |
| SCHEMBL9816494 | 0.79 | MAPT (0.70) | MEN1KMT2AKDM4EGAAGFER | |
| SCHEMBL9816506 | 0.78 | KDM4E (1.00) | MEN1KMT2AKDM4EGAAGFER | |
| SCHEMBL3107640 | 0.76 | MAPT (0.63) | MEN1KMT2AKDM4EGAAGFER | |
| SCHEMBL6257175 | 0.76 | KMT2A (0.69) | MEN1KMT2AKDM4EGAAMAPT | |
| SCHEMBL8541848 | 0.75 | MEN1 (0.72) | MEN1KMT2AKDM4EGAAGFER | |
| SCHEMBL7469842 | 0.72 | KMT2A (0.55) | MEN1KMT2AKDM4EGAAGFER | |
| SCHEMBL7833634 | 0.71 | KDM4E (0.66) | MEN1KMT2AKDM4EGAAGFER | |
| SCHEMBL29177155 | 0.71 | HPGD (0.68) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL27785395 | 0.71 | MEN1 (0.66) | MEN1KMT2AKDM4EGAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2089381-B1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-2089381-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080269290-A1 | Indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008068184-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139617-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139548-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | MEN1 1712/4885KMT2A 1042/4885KDM4E 1393/4885 |
| US-20080139617-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | MEN1 1712/4885KMT2A 1042/4885KDM4E 1393/4885 |
| US-20080269290-A1 | Indoles | HTR1A, AVPR1A, TPH1 | MEN1 1712/4885KMT2A 1042/4885KDM4E 1393/4885 |
| US-20080139618-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | MEN1 1712/4885KMT2A 1042/4885KDM4E 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.